Diseases
Huntington's disease (HD) is a rare, inherited neurodegenerative disease, leading to progressive neuronal death and manifesting as a decline in cognitive, behavioral, and motor functions.
HD is not very common, affecting 4.88 in every 100,000 people1. The disease usually manifests during mid-adult life (between ages 35 and 55), but a small percentage develop symptoms before the age of 20 (this is known as juvenile HD)2.
HD causes a combination of motor, psychiatric, and cognitive symptoms that can vary greatly between individuals4. Motor problems often include involuntary movements (chorea) and difficulties with voluntary control. Psychiatric and behavioural changes—such as depression, apathy, irritability, and anxiety—are common and may appear early in the disease5. Cognitive symptoms, particularly executive dysfunction, frequently emerge before clear motor signs6. The disease typically progresses over 15 to 20 years after onset4, leading to increasing difficulties with behaviour, thinking, and movement, and eventually causing severe disability and death.
We join forces with large companies with the purpose of providing solutions to the challenges of Barcelona
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
Ferrer included in the ranking of the most ethical companies in the world in 2026
Last updated: July 2026
